July 11, 2009 |
Biotechnology company Amgen Inc. said Rebecca Henderson had been appointed to its board of directors. Henderson, 48, recently became a professor at Harvard Business School. She has been a director at Idexx Laboratories Inc. since 2003. Her appointment expands the size of Thousand Oaks-based Amgen's board to 13.
March 11, 2006 |
Amgen Inc. said U.S. prosecutors had requested documents relating to the drug maker's relationship with an unidentified pharmacy company. Thousand Oaks-based Amgen said it received the subpoena last month. The U.S. attorney's office in Massachusetts is seeking the documents.
June 16, 2007 |
A House committee asked for documents related to the advertising of anemia drugs made by Thousand Oaks-based Amgen Inc. and Johnson & Johnson as part of an investigation into the ability of U.S. regulators to protect consumers from dangerous medications. Democrats on the House Energy and Commerce Committee asked the Health and Human Services Department for records on the marketing of the drugs, Amgen's Aranesp and J&J's Procrit.
March 15, 2007 |
Use of the anemia drugs Aranesp and Epogen, made by Thousand Oaks-based Amgen Inc., and Procrit, sold by Johnson & Johnson, will be reviewed by U.S. government health insurance programs. The study of the drugs for uses other than end-stage renal diseases was announced by the Centers for Medicare and Medicaid Services.
March 7, 2008 |
Amgen Inc. will pay Kyowa Hakko Kogyo Co. $100 million initially and as much as $420 million tied to the development of an experimental medicine for inflammation and cancer, the companies said. Kyowa Hakko is the Tokyo-based drug unit of Kirin Holdings Co. The deal gives Thousand Oaks-based Amgen a potential medication that could join its anti-inflammatory medicine Enbrel. Shares fell $1.01 to $44.24.
April 17, 1998
Consumer activist Ralph Nader lashed out at Thousand Oaks-based Amgen Inc., saying it's suppressing research that could improve its top-selling drug, Epogen, because it would hurt sales. In letters to President Clinton and Amgen executives, Nader charged that the company failed to support research that could improve Epogen's effectiveness. Epogen is used to treat anemia in patients with kidney failure. It generates $1 billion in annual sales. An Amgen spokesman declined to comment.
April 4, 2008 |
Sen. Charles E. Grassley (R-Iowa) said he had asked Amgen Inc. to "account for notably high rebates" the company had offered physicians for prescribing Aranesp, an anemia drug. Thousand Oaks-based Amgen paid almost $800 million in rebates to 6,000 facilities, including physician groups, in 2006, Grassley said, citing company data. Doctors collected payments from Medicare and insurers that exceeded the price they paid for the drugs, he said. An Amgen spokeswoman said the company provided rebates, like many of its competitors, to its customers.
May 18, 2002 |
Celltech Group will work with Amgen Inc. on treatments for osteoporosis, a loss of bone density that can lead to fractures in elderly patients. Amgen gets marketing rights to Celltech drugs that target a protein linked to the illness, said Peter Allen, Celltech's finance director. Celltech will pay some costs until the end of Phase II tests and may opt to get some European rights. Shares of Celltech, Britain's largest biotechnology company, rose 55 cents to $16.85 on the NYSE.
November 1, 2002 |
Amgen Inc. will get a "significantly" smaller reimbursement next year for its Aranesp anemia drug for some patients on Medicare under new rules announced by the U.S. health insurance program. The Centers for Medicare & Medicaid Services now will pay hospitals less for Medicare patients receiving Aranesp in outpatient settings. About 10% of Aranesp's revenue comes from U.S. hospital outpatient reimbursements, the company said.